awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E
Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
P2860
Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1b8abd5e02d195e9fa1ab80cecd3e77fe9f5c329
P2860
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial